Enabling ISARIC Clinical Characterisation Protocol (CCP) roll out in LMICs

By bringing GOARN Research and ISARIC partners together in the LMIC setting during COVID-19 we hope to strengthen the clinical, social science and operational research response.

Aim: to support the roll out of the ISARIC WHO natural history protocol (known as the Clinical Characterisation Protocol - CCP) across LMICs: Overarching goals: - Support the roll out/uptake of the CCP across 5 countries per region, where feasible* (across four ISARIC regions of S America, Africa, S Asia & SE Asia). - Support the set up and running of local dynamic clinical data dashboards in at least 10 sites per ISARIC region - Share the aggregate data with WHO to assist with providing a global picture on the incidence and presentation of moderate to severe cases across a representation of the LMICs to inform clinical management and public health planning and control. - Support the establishment of follow up modules and programmes for discharged hospitalised cases in 5 sites per region to evaluate longer term health impacts of COVID-19 on individual, health services and society to inform prevention and care planning. *Brazil are in an intense first wave and reaching out to another 4 S.

American countries would be challenging at the time of writing.